Published in Hum Pathol on March 01, 1992
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Histopathological image analysis: a review. IEEE Rev Biomed Eng (2009) 6.86
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol (2009) 2.94
Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol (2015) 2.06
Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol (2008) 2.01
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet (2000) 1.57
High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol (2003) 1.57
Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy. Eur Urol (2012) 1.50
Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2004) 1.42
Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia (2000) 1.34
Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.33
A molecular signature predictive of indolent prostate cancer. Sci Transl Med (2013) 1.32
Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer (2005) 1.26
Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int (2011) 1.26
The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch (2006) 1.25
Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am (2008) 1.24
Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol (2008) 1.23
p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate (2008) 1.19
Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate (2012) 1.18
Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging (2005) 1.17
Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia (2002) 1.11
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer (2001) 1.08
Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer (1999) 1.07
Two susceptibility loci identified for prostate cancer aggressiveness. Nat Commun (2015) 1.06
Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate (2011) 1.06
Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol (2002) 1.04
Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays. J Cancer Res Clin Oncol (2008) 1.03
Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res (2014) 1.01
Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration. Oncotarget (2014) 1.01
Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch (2004) 1.00
Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment. NMR Biomed (2011) 0.99
Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance. Virchows Arch (2003) 0.98
Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol (2010) 0.98
Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors. Neoplasia (2007) 0.97
8q24 sequence variants in relation to prostate cancer risk among men of African descent: a case-control study. BMC Cancer (2010) 0.97
How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. Health Inf Sci Syst (2013) 0.96
A high-throughput active contour scheme for segmentation of histopathological imagery. Med Image Anal (2011) 0.96
Association of CD14 variant with prostate cancer in African American men. Prostate (2010) 0.95
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol (2003) 0.95
Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch (2004) 0.95
Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer (2008) 0.94
Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer (2007) 0.92
Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol (1997) 0.92
Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol (2012) 0.91
Green tea and prostate cancer: from bench to clinic. Front Biosci (Elite Ed) (2009) 0.88
Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. Hum Pathol (2012) 0.88
Prostate cancer susceptibility loci: finding the genes. Adv Exp Med Biol (2008) 0.87
Reproducibility and reliability of tumor grading in urological neoplasms. World J Urol (2007) 0.87
Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl (2012) 0.86
Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med (2012) 0.85
Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors. Oncol Lett (2012) 0.84
In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J Nucl Med (2009) 0.84
Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis (2016) 0.82
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol (2015) 0.82
Frequency and determinants of disagreement and error in gleason scores: a population-based study of prostate cancer. Prostate (2012) 0.82
Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues. Biomed Opt Express (2015) 0.82
Emergent trends in the reported incidence of prostate cancer in Nigeria. Clin Epidemiol (2012) 0.81
Mitochondrial haplogroups and polymorphisms reveal no association with sporadic prostate cancer in a southern European population. PLoS One (2012) 0.81
Pathological correlation between needle biopsy and radical prostatectomy specimen in patients with localized prostate cancer. Can Urol Assoc J (2007) 0.81
DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. Urology (2009) 0.81
Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status. Am J Epidemiol (2015) 0.81
Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. Am Soc Clin Oncol Educ Book (2016) 0.81
Biomarker identification with ligand-targeted nucleoprotein assemblies. Nanomedicine (Lond) (2011) 0.81
Alcohol exposure in utero increases susceptibility to prostate tumorigenesis in rat offspring. Alcohol Clin Exp Res (2013) 0.80
Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol (1997) 0.80
Edge effects in game-theoretic dynamics of spatially structured tumours. J R Soc Interface (2015) 0.79
Identifying Clinically Significant Prostate Cancers using 3-D In Vivo Acoustic Radiation Force Impulse Imaging with Whole-Mount Histology Validation. Ultrasound Med Biol (2016) 0.79
Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker. Oncol Lett (2015) 0.79
Detection of infectious organisms in archival prostate cancer tissues. BMC Cancer (2014) 0.79
The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer. Int J Clin Exp Pathol (2011) 0.79
A microdissection approach to detect molecular markers during progression of prostate cancer. Br J Cancer (1995) 0.78
Gleason scoring at a comprehensive cancer center: what's the difference? J Natl Compr Canc Netw (2013) 0.78
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. Int J Clin Oncol (2016) 0.78
Human cancer classification: a systems biology- based model integrating morphology, cancer stem cells, proteomics, and genomics. J Cancer (2011) 0.78
Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study. World J Urol (2010) 0.77
Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys (2008) 0.77
Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer. Prostate (2016) 0.77
Near-infrared fluorescent digital pathology for the automation of disease diagnosis and biomarker assessment. Mol Imaging (2015) 0.77
Pseudolumen size and perimeter in prostate cancer: correlation with patient outcome. Prostate Cancer (2011) 0.77
Isolation and analysis of discreet human prostate cellular populations. Differentiation (2015) 0.77
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). Pathol Oncol Res (1996) 0.76
Factors predicting Gleason score 6 upgrading after radical prostatectomy. Cent European J Urol (2011) 0.76
Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed? Prostate Cancer Prostatic Dis (2017) 0.76
[Gleason grading: diagnostic criteria and clinical implications]. Pathologe (2005) 0.75
Correlation between Gleason Scores in Needle Biopsy and Corresponding Radical Prostatectomy Specimens: A Twelve-Year Review. Iran J Pathol (2016) 0.75
Differences in the structural features of atypical adenomatous hyperplasia and low-grade prostatic adenocarcinoma. Indian J Urol (2008) 0.75
Final Gleason score prediction using discriminant analysis and support vector machine based on preoperative multiparametric MR imaging of prostate cancer at 3T. Biomed Res Int (2014) 0.75
Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer. Am J Pathol (2012) 0.75
Potential clinical importance of the activation peptide of prostate-specific antigen. Int J Clin Exp Pathol (2009) 0.75
Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification. Oncotarget (2017) 0.75
Subspecialty surgical pathologist's performances as triage pathologists on a telepathology-enabled quality assurance surgical pathology service: A human factors study. J Pathol Inform (2014) 0.75
Gleason score and tumor laterality in radical prostatectomy and transrectal ultrasound-guided biopsy of the prostate: a comparative study. Asian J Androl (2015) 0.75
Microscopic medical image classification framework via deep learning and shearlet transform. J Med Imaging (Bellingham) (2016) 0.75
Survey of clinical and pathological characteristics and outcomes of patients with prostate cancer. Glob J Health Sci (2014) 0.75
Automated prostate tissue referencing for cancer detection and diagnosis. BMC Bioinformatics (2016) 0.75
Immunochemiluminescent detection of galectin-3 in tumoral tissue from prostate. Int J Clin Exp Pathol (2013) 0.75